Your browser doesn't support javascript.
loading
Anaphylaxis associated with omalizumab administration: Risk factors and patient characteristics.
Lieberman, Phillip L; Jones, Ilisten; Rajwanshi, Richa; Rosén, Karin; Umetsu, Dale T.
Affiliation
  • Lieberman PL; Departments of Internal Medicine and Pediatrics, Division of Allergy and Immunology, University of Tennessee College of Medicine, Memphis, Tenn. Electronic address: phillieberman@hotmail.com.
  • Jones I; Department of Pediatrics, Division of Allergy and Immunology, University of California, San Francisco, Calif.
  • Rajwanshi R; Genentech, Inc, South San Francisco, Calif.
  • Rosén K; Genentech, Inc, South San Francisco, Calif.
  • Umetsu DT; Department of Pediatrics, Division of Allergy and Immunology, University of California, San Francisco, Calif; Genentech, Inc, South San Francisco, Calif.
J Allergy Clin Immunol ; 140(6): 1734-1736.e4, 2017 12.
Article in En | MEDLINE | ID: mdl-28797731
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Anti-Allergic Agents / Omalizumab / Anaphylaxis Type of study: Etiology_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged Language: En Journal: J Allergy Clin Immunol Year: 2017 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Anti-Allergic Agents / Omalizumab / Anaphylaxis Type of study: Etiology_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged Language: En Journal: J Allergy Clin Immunol Year: 2017 Document type: Article